Services

Statistical and pharmacometric support for clinical development programs, from early planning through regulatory submission.

Study design, protocols and statistical analysis plans

  • Protocol statistical sections: objectives, endpoints, estimands and analysis populations
  • Sample size and statistical power calculations, with documented assumptions and sensitivity analyses
  • Statistical analysis plans (SAPs), including table, listing and figure (TLF) shells
  • Randomization and stratification specifications
  • Simulation studies to compare designs and operating characteristics
  • Missing data, intercurrent events and sensitivity analyses

Interim analyses and Type I error control

  • Efficacy and futility interim analyses for time-to-event, binary and continuous endpoints
  • Safety monitoring plans and interim safety analyses
  • Group sequential designs with alpha-spending functions (O'Brien-Fleming-type, Pocock-type and Lan-DeMets approaches)
  • Multiplicity control across endpoints, doses and subgroups: fixed-sequence, Bonferroni, Holm, Hochberg, gatekeeping and graphical approaches
  • Adaptive designs: sample size re-estimation, population enrichment, seamless phase transitions
  • Bayesian monitoring and decision rules
  • DMC/DSMB charters, analysis plans and unblinded reporting packages

Therapeutic areas

  • Oncology: progression-free and overall survival, response endpoints, restricted mean survival time, non-proportional hazards, basket, umbrella and platform designs
  • Hematology: response and durability endpoints, transfusion and bleeding-rate outcomes, small-population designs
  • Gene therapy: small-sample designs, durability of effect, long-term follow-up and natural-history comparisons
  • Rare diseases: efficient designs for very small populations, external and historical controls, Bayesian borrowing
  • Cardiovascular and medical devices: non-inferiority and superiority designs, performance goals, Bayesian device trials, composite endpoints
  • Neurological conditions: longitudinal and repeated-measures analyses, disease-progression endpoints, responder analyses

Regulatory submission support

  • Statistical support for BLA, MAA and other marketing applications
  • Integrated summary of safety (ISS) and integrated summary of efficacy (ISE): analysis plans, pooling strategy and outputs
  • Statistical sections of clinical study reports and submission documents
  • Meeting packages and briefing documents for regulatory interactions
  • Responses to regulatory questions that need statistical analyses or justification

Data standards and programming

  • SDTM and ADaM datasets, including ADSL and analysis datasets for efficacy and safety
  • Define-XML, annotated case report forms and reviewer's guides
  • Dataset and specification validation, including Pinnacle 21 review and issue resolution
  • Tables, listings and figures programming in R and SAS
  • Independent QC and double programming
  • Validation of existing programs and reproducible, documented workflows

Pharmacometrics and model-informed drug development

  • PK/PD analyses: noncompartmental, compartmental and population approaches
  • Exposure-response analyses
  • PBPK model building, evaluation and simulation
  • Model-informed drug development (MIDD) analyses that support dose selection and development decisions
  • Quantitative systems pharmacology (QSP) modeling and simulation
How we work: Our work supports analysis and decision-making. We do not provide medical advice, and regulatory outcomes depend on many factors beyond any statistical analysis. Work begins only after the scope, timeline and terms are agreed in writing.

Request an analysis

Clinical Biostats